CN1724552A - Preparation method of astilbin - Google Patents
Preparation method of astilbin Download PDFInfo
- Publication number
- CN1724552A CN1724552A CN200510040944.2A CN200510040944A CN1724552A CN 1724552 A CN1724552 A CN 1724552A CN 200510040944 A CN200510040944 A CN 200510040944A CN 1724552 A CN1724552 A CN 1724552A
- Authority
- CN
- China
- Prior art keywords
- astilbin
- preparation
- ethanol
- weight
- recrystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZROGCCBNZBKLEL-FHXNIQKESA-N Astilbin Natural products O([C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O)[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 ZROGCCBNZBKLEL-FHXNIQKESA-N 0.000 title claims abstract description 57
- ZROGCCBNZBKLEL-MPRHSVQHSA-N astilbin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1C(=O)C2=C(O)C=C(O)C=C2O[C@@H]1C1=CC=C(O)C(O)=C1 ZROGCCBNZBKLEL-MPRHSVQHSA-N 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 92
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 25
- 239000000463 material Substances 0.000 claims abstract description 24
- 238000001556 precipitation Methods 0.000 claims abstract description 18
- 238000000605 extraction Methods 0.000 claims abstract description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920005989 resin Polymers 0.000 claims abstract description 11
- 239000011347 resin Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004952 Polyamide Substances 0.000 claims abstract description 9
- 229920002647 polyamide Polymers 0.000 claims abstract description 9
- 238000005238 degreasing Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000003208 petroleum Substances 0.000 claims abstract description 6
- 238000001953 recrystallisation Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 239000012452 mother liquor Substances 0.000 claims description 8
- 241001002544 Engelhardia Species 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 238000000151 deposition Methods 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000003480 eluent Substances 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 34
- 239000000243 solution Substances 0.000 description 25
- 239000000469 ethanolic extract Substances 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 241001092376 Astilbe Species 0.000 description 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 2
- 240000009022 Smilax rotundifolia Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compound Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a process for preparing astilbin which comprises the steps of disintegrating medicinal materials, extracting with aqueous solutions of ethanol with two concentrations, degreasing the 90-95 wt% water raffinate of ethanol with petroleum ether, condensing into concrete, alcohol-depositing the concrete, merging the mother liquid with 20-80 wt% water raffinate of ethanol, concentrating and extracting with ethanol-containing acetic ester liquid, alcohol-depositing the extract and mixing with the precipitation, dissolving then passing through macro-porous absorption resin or polyamide columns, eluting with 20-80 wt% aqueous solution of ethanol, finally recrystallizing the eluent. The extraction rate of astilbin is over 50%, and the content of astilbin is over 90%.
Description
One, technical field
The present invention relates to a kind of method that from Chinese medicinal materials Folium Engelhardia roxburghina (Engelhardria roxburghiana Wall), prepares astilbin.
Two, background technology
Astilbin (astilbin) 3,3,4 ', 5,7-pentahydroxyflavanone3-(6-deoxy-(L-mannopyranoside)) is a kind of flavonoid compound, and nineteen fifty is extracted from the plant Herba astilbes chinensis first by KozoHayashi and Kazuhiko Ouchi and obtains.The structural formula of astilbin is as follows:
Bibliographical information, astilbin have desinsection (Pest Manag.Sci.2002; 58:503-507), suppress CoA-reductase (Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64:382-387), suppress aldose reductase (Biosci.Biotechnol.Biochem.1997; 61:651-654), liver protection (Prostaglandins Leukot Essent Fatty Acids 1997; (Arzneimittelforschung 2000 for 56:331-334), analgesia, Ivy extract; 50:281-285), anti-oxidant (Biosci.Biotechnol.Biochem.1996; 60:513-515) isoreactivity, astilbin can also significantly improve immunological liver injury (Eur.J.Pharmacol.1999; 377:93-100; J.Pharm.Pharmacol.2004 56:495-502), induces PHA activatory Jurkat apoptosis (Pharmacol.Res.2001; 44:135-139), suppress delayed type hypersensitivity and treatment mouse collagen type sacroiliitis (Inflamm Res.2003 by the function that suppresses activated T lymphocytes; 52 (8): 334-40.J.Pharm.Pharmacol.2003; 55:691-696) etc.
At present the main source of astilbin is therefrom to extract in sphragidite Poria cocos or the Herba astilbes chinensis, and the content of astilbin in the Rhizome of Glabrous Greenbrier is because kind, the place of production, product are received the difference in season, and content does not wait at 0.1%-2.0%.And at the Huang Qishu of ground such as Guangxi China, Guizhou growths, contained astilbin amount in its leaf all is several times as much as the content in the Rhizome of Glabrous Greenbrier, and yellow Qi leaf only is used as tealeaves for a long time and uses in the locality, obviously wasted valuable resource.
Three, summary of the invention
1, goal of the invention: the purpose of this invention is to provide a kind of preparation method that can obtain the simple astilbin that can be used for suitability for industrialized production of astilbin in a large number.
2, technical scheme: the preparation method of astilbin of the present invention is characterized in that this method may further comprise the steps:
(1) will be that ethanol and the concentration of 90%-95% (weight) is the ethanol percolate extraction of 20%-80% (weight) through over-richness successively after the Folium Engelhardia roxburghina pulverizing medicinal materials;
(2) the extraction using alcohol gained extracting solution with 90%-95% in the step (1) is condensed into medicinal extract, the medicinal extract alcohol precipitation behind petroleum ether degreasing;
(3) with in mother liquid obtained and the step (1) in the step (2) with the extraction using alcohol gained extracting solution of 20%-80% merge concentrate after, with ethyl acetate or contain the alcoholic acid ethyl acetate extraction, extract carries out alcohol precipitation;
(4) with after step (2) and step (3) the gained throw out merging dissolving, cross macroporous adsorbent resin or polyamide column, with concentration is the aqueous ethanolic solution wash-out of 20%-80% (weight), and elutriant volatilizes solvent and gets the astilbin crude product, gets the pure product of astilbin through recrystallization again;
(5) the gained recrystallization mother liquor is crossed macroporous adsorbent resin or polyamide column once more, with the aqueous ethanolic solution wash-out of 20%-80% (weight), elutriant gets the pure product of astilbin through recrystallization after volatilizing solvent again.
In step (1), before extracting pulverizing medicinal materials is become meal; The aqueous ethanolic solution of used 90%-95%, its consumption are 13 times to 20 times of used medicinal material weight, preferred 15 times; The aqueous ethanolic solution of used 20%-80%, its consumption are 5 times to 15 times of used medicinal material weight, preferred 7 times; The soak time of medicinal material is 2-12 hour, and diacolation extraction time is 1-12 hour, preferred 3-10 hour, and more preferably 5-8 hour.
In step (2), the sherwood oil consumption is a 1-4 times of weight of used medicinal material weight, preferred 2-3 times of weight, most preferably 2 times of weight; Used ethanol is the aqueous ethanolic solution of various concentration in the medicinal extract alcohol precipitation, adds the aqueous ethanolic solution post precipitation, and the ethanol ultimate density in the mixed solution can be a 0-95% weight, preferred 20%-80% weight, most preferably 50% weight.
In step (3), the volume of concentrated solution is 0.2-1 a times of used medicinal material volume, preferred 0.5 times; Extraction can be to contain 0%-20% (volume) alcoholic acid acetic acid ethyl fluid with acetic acid ethyl fluid, most preferably contains
10% (volume) alcoholic acid ethyl acetate solution; Ethyl acetate or the consumption that contains the alcoholic acid ethyl acetate be used medicinal material weight 1-4 doubly, preferred 2-3 doubly, most preferably 2.5 times.
In step (4), used polymeric adsorbent is the macroporous adsorbent resin of polymeric amide or various models, preferred macroporous adsorbent resin, more preferably nonpolar macroporous adsorption resin; Elutriant is the aqueous ethanolic solution of concentration 20%-80% (weight), the aqueous ethanolic solution of preferred 20%-70%, most preferably 30% weight; The recrystallization solvent for use can adopt water or organic solvent, and organic solvent can adopt various organic solvents commonly used such as ethanol, methyl alcohol, chloroform or ethyl acetate, the preferred alcohol aqueous solution, most preferably 50% weight aqueous ethanolic solution; The number of times of recrystallization can be 1-5 time, preferably twice.
3, beneficial effect: adopt astilbin extracting method of the present invention, (1) extracts astilbin from Folium Engelhardia roxburghina, extracts yield more than 50%, and the purity of astilbin is more than 90%.(2) astilbin of employing the inventive method gained, through measuring by 2005 editions high performance liquid chromatography of the Pharmacopoeia of the People's Republic of China, the result shows that the content of astilbin is higher than 90% in the extract, shows feasible process of the present invention.(3) astilbin extracting method of the present invention, it is simple to have extraction process, and cost is low, and the extraction yield height extracts the characteristics such as astilbin monomer purity height that obtain, and is applicable to suitability for industrialized production.
Four, embodiment
Be embodiments of the invention below, but the present invention is not limited only to described embodiment.
Embodiment 1: the Folium Engelhardia roxburghina pulverizing medicinal materials is become meal, with 95% ethanol of 10 times of medicinal material weight and the 80% ethanol diacolation extraction respectively of 15 times of amounts, collect percolate.95% ethanol extract with petroleum ether degreasing after, be concentrated into medicinal extract, adding ethanol, to make strength of solution be 20% aqueous ethanolic solution, and the dissolving back is placed and analysed precipitation, divides and gets precipitation, mother liquor and 80% ethanol extract merge, be concentrated into every milliliter 3 gram crude drug, with the ethyl acetate extraction that is equivalent to 2 times of amounts of crude drug, acetic acid ethyl ester extract is concentrated into medicinal extract, adding aqueous ethanolic solution, to make strength of solution be 20% aqueous ethanolic solution, and the dissolving back is placed and analysed precipitation.Divide and get precipitation, ethanol precipitation twice gained precipitation is merged, cross polyamide column after the water dissolution, with distilled water wash post bed, with 60% weight aqueous ethanolic solution wash-out, after elutriant is flung to solvent, 20% weight aqueous ethanolic solution recrystallization gets astilbin, mother liquor is flung to the alcohol back after polyamide column behind the recrystallization, and 60% weight aqueous ethanolic solution wash-out, elutriant are used 20% weight ethanol water recrystallization after flinging to solvent again.Get astilbin, extraction yield is 51.4%, and astilbin content is 90%.
Embodiment 2: the Folium Engelhardia roxburghina pulverizing medicinal materials is become meal, 60% ethanol diacolation extraction respectively with 15 times of 90% ethanol of medicinal material weight and 10 times of amounts, collect 90% ethanol extract and 60% ethanol extract, 90% ethanol extract is concentrated into medicinal extract with extracting solution after with petroleum ether degreasing, it is the aqueous ethanolic solution of 60% weight that adding ethanol makes strength of solution, dissolving, precipitation is analysed in placement, mother liquor merges behind 60% ethanol extract and the aforementioned alcohol precipitation, concentrate the back with containing 5% alcoholic acid ethyl acetate extraction, acetic acid ethyl ester extract is concentrated into and adds ethanol behind the medicinal extract to make alcohol concn be 60%, the dissolving back is placed and is analysed precipitation, and ethanol precipitation twice gained precipitation is merged, and crosses LSA-10 macroporous resin (blue dark production the in Xi'an) post after the water dissolution, with 70% ethanolic soln wash-out, after elutriant was flung to solvent, 60% ethyl alcohol recrystallization got the astilbin monomer, and mother liquor is flung to the alcohol back after the LSA-7 macroporous resin column behind the recrystallization, 70% ethanol elution, elutriant are used 60% ethyl alcohol recrystallization after flinging to solvent again.Get astilbin, content is 90%, and extraction yield is 53.5%.
Embodiment 3: the Folium Engelhardia roxburghina pulverizing medicinal materials, extract with 20 times of 95% ethanol of medicinal material weight and 8 times of amount 20% ethanol gradient diacolations, collect 95% ethanol extract and 40% ethanol extract respectively, 95% ethanol extract is concentrated into medicinal extract with extracting solution after with petroleum ether degreasing, place after the water dissolution and analyse precipitation, mother liquor merges concentrated back with containing 20% alcoholic acid ethyl acetate extraction behind 40% ethanol extract and the aforementioned alcohol precipitation, ethyl acetate extract is concentrated into and adds ethanol behind the medicinal extract to make alcohol concn be 80%, place the dissolving back, ethanol precipitation twice gained precipitation is merged, cross polyamide column after the water dissolution, with 50% ethanolic soln wash-out, after elutriant is flung to solvent, 70% ethyl alcohol recrystallization gets the astilbin monomer, mother liquor is flung to the alcohol back after polyamide column behind the recrystallization, and 50% ethanol elution, elutriant are used 70% ethyl alcohol recrystallization after flinging to solvent again.Content is 90% astilbin, extraction yield is 52.8%.
Embodiment 4: the experiment of astilbin purity testing.It is an amount of to get the astilbin monomer that the said extracted method prepares, and the dissolve with methanol constant volume behind the filtering with microporous membrane, injects high performance liquid chromatograph in volumetric flask, with Pharmacopoeia of the People's Republic of China high effective liquid chromatography for measuring content in 2005.
Chromatographic condition: Water 600 high performance liquid chromatographs, Waters 2487 UV-detector; Chromatographic column: Symmetry C18 post (4.6mm * 250mm, 5 μ m); Moving phase: methyl alcohol-Glacial acetic acid-water (45: 1: 54); Detect wavelength: 291nm; Column temperature: 30 ℃; Flow velocity: 1ml/min; Sample size: 5 μ l.
The reference substance astilbin, self-control, colourless needle crystal, mp182～186 ℃, through mensuration such as UV, IR, 1H-NMR, 13C-NMR, MS, its data are consistent with bibliographical information, are accredited as astilbin.Be single spot on the TLC collection of illustrative plates, HPLC detects to unimodal, and normalization method content is more than 99%.
Measure as stated above, the content of astilbin is more than 90% in the extract.
In sum, astilbin extracting method of the present invention can extract from the medicinal material that contains astilbin effectively and obtain astilbin, and astilbin content all is higher than more than 90% in the extract, and the technology simple possible, and cost is low, is applicable to suitability for industrialized production.
The extracting method of astilbin disclosed in this invention has as above been described.But need to understand and wherein comprised variation understood by one of ordinary skill in the art and change.These variations and change are also contained in the basis that claim limits
In the scope of invention.
Claims (10)
1, a kind of preparation method of astilbin is characterized in that this method may further comprise the steps:
(1) will be that ethanol and the concentration of 90%-95% (weight) is the ethanol percolate extraction of 20%-80% (weight) through over-richness successively after the Folium Engelhardia roxburghina pulverizing medicinal materials;
(2) the extraction using alcohol gained extracting solution with 90%-95% in the step (1) is condensed into medicinal extract, the medicinal extract alcohol precipitation behind petroleum ether degreasing;
(3) with in mother liquid obtained and the step (1) in the step (2) with the extraction using alcohol gained extracting solution of 20%-80% merge concentrate after, with ethyl acetate or contain the alcoholic acid ethyl acetate extraction, extract carries out alcohol precipitation;
(4) with after step (2) and step (3) the gained throw out merging dissolving, cross macroporous adsorbent resin or polyamide column, with concentration is the aqueous ethanolic solution wash-out of 20%-80% (weight), and elutriant volatilizes solvent and gets the astilbin crude product, gets the pure product of astilbin through recrystallization again;
(5) the gained recrystallization mother liquor is crossed macroporous adsorbent resin or polyamide column once more, with the aqueous ethanolic solution wash-out of 20%-80% (weight), elutriant gets the pure product of astilbin through recrystallization after volatilizing solvent again.
2, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (1), and the aqueous ethanolic solution of used 90%-95%, its consumption are 13-20 times of used medicinal material weight.
3, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (1), and the aqueous ethanolic solution of used 20%-80%, its consumption are 5-15 times of used medicinal material weight.
4, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (1), the soak time of medicinal material is 2-12 hour, and diacolation extraction time is 1-12 hour.
5, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (2), and the sherwood oil consumption is 1-4 a times of used medicinal material weight.
6, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (3), and the volume of concentrated solution is 0.2-1 a times of used medicinal material volume.
7, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (3), ethyl acetate or the consumption that contains the alcoholic acid ethyl acetate be used medicinal material weight 1-4 doubly.
8, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (4), used polymeric adsorbent is the macroporous adsorbent resin of polymeric amide or various models.
9, the preparation method of a kind of astilbin according to claim 1 is characterized in that in step (4), elutriant is the aqueous ethanolic solution of concentration 20%-80% (weight).
10, the preparation method of a kind of astilbin according to claim 1 is characterized in that the recrystallization solvent for use can adopt water or organic solvent in step (4), and organic solvent can adopt ethanol, methyl alcohol, chloroform or ethyl acetate organic solvent; The number of times of recrystallization can be 1-5 time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100409442A CN100348606C (en) | 2005-07-08 | 2005-07-08 | Preparation method of astilbin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100409442A CN100348606C (en) | 2005-07-08 | 2005-07-08 | Preparation method of astilbin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1724552A true CN1724552A (en) | 2006-01-25 |
| CN100348606C CN100348606C (en) | 2007-11-14 |
Family
ID=35924195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100409442A Expired - Fee Related CN100348606C (en) | 2005-07-08 | 2005-07-08 | Preparation method of astilbin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100348606C (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100348610C (en) * | 2005-09-01 | 2007-11-14 | 桂林莱茵生物科技股份有限公司 | Method for extracting astilbin from engelhardtia leaves |
| CN101935332A (en) * | 2010-07-16 | 2011-01-05 | 沈阳药科大学 | Preparation method and application of 5,7,4'-trihydroxyl8-methoxyl-3-O-alpha-L-rhamnoside and active composition thereof |
| CN101972287A (en) * | 2010-10-18 | 2011-02-16 | 山东大学威海分校 | Preparation method of Chinese astilbe extract and purpose thereof |
| CN102020690A (en) * | 2010-11-09 | 2011-04-20 | 苏州派腾生物医药科技有限公司 | Preparation method of astilbin |
| CN102432652A (en) * | 2010-09-29 | 2012-05-02 | 苏州瑞蓝博中药技术开发有限公司 | Method for extracting astilbin from china root |
| CN103012522A (en) * | 2012-12-28 | 2013-04-03 | 顾玲 | Purification process of astilbin |
| CN103768082A (en) * | 2012-10-18 | 2014-05-07 | 滨州医学院 | Application of astilbin to preparation of medicament for treating or preventing diabetes accompanied with stroke |
| CN105061531A (en) * | 2015-07-29 | 2015-11-18 | 成都大学 | Astilbe chinensis glycoside derivatives and preparation method thereof |
| CN106565804A (en) * | 2016-10-10 | 2017-04-19 | 广西来宾绿翔生物科技有限公司 | Extraction technology of Engelhardia roxburghiana Wall leaf astilbin |
| CN107056858A (en) * | 2017-04-28 | 2017-08-18 | 南宁馨艺荣生物科技有限公司 | Process for extracting astilbin from engelhardtia leaves |
| CN107951923A (en) * | 2017-12-07 | 2018-04-24 | 广西壮族自治区中医药研究院 | A kind of preparation method of astragalus leaf flavonoids and its application in protection blood vessel drug eluting is prepared |
| CN109369749A (en) * | 2018-11-30 | 2019-02-22 | 陕西嘉禾生物科技股份有限公司 | A kind of preparation method of Astilbin |
| CN111437302A (en) * | 2015-05-25 | 2020-07-24 | 蔡世珍 | Application of extract of engelhardtia leaves after water extraction and macroporous resin treatment in preparation of diabetes drugs and analysis method thereof |
| CN111440221A (en) * | 2019-12-13 | 2020-07-24 | 湖南甜蔓生物科技有限公司 | Astilbin prepared from Engelhardtia chrysolepis Hance leaf and its preparation method |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101982183A (en) * | 2010-10-18 | 2011-03-02 | 山东大学威海分校 | Preparation method of Astilbe chinensis root extract and antioxidant application of Astilbe chinensis root extract |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3226700B2 (en) * | 1994-02-07 | 2001-11-05 | 丸善製薬株式会社 | Whitening agent and skin external preparation |
| CN1279052C (en) * | 2004-03-11 | 2006-10-11 | 南开大学 | Process for extracting total flavone and total oside of astragalus from astragalus |
-
2005
- 2005-07-08 CN CNB2005100409442A patent/CN100348606C/en not_active Expired - Fee Related
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100348610C (en) * | 2005-09-01 | 2007-11-14 | 桂林莱茵生物科技股份有限公司 | Method for extracting astilbin from engelhardtia leaves |
| CN101935332A (en) * | 2010-07-16 | 2011-01-05 | 沈阳药科大学 | Preparation method and application of 5,7,4'-trihydroxyl8-methoxyl-3-O-alpha-L-rhamnoside and active composition thereof |
| CN101935332B (en) * | 2010-07-16 | 2014-06-25 | 沈阳药科大学 | Preparation method and application of 5,7,4'-trihydroxyl8-methoxyl-3-O-alpha-L-rhamnoside and active composition thereof |
| CN102432652A (en) * | 2010-09-29 | 2012-05-02 | 苏州瑞蓝博中药技术开发有限公司 | Method for extracting astilbin from china root |
| CN101972287A (en) * | 2010-10-18 | 2011-02-16 | 山东大学威海分校 | Preparation method of Chinese astilbe extract and purpose thereof |
| CN102020690A (en) * | 2010-11-09 | 2011-04-20 | 苏州派腾生物医药科技有限公司 | Preparation method of astilbin |
| CN103768082B (en) * | 2012-10-18 | 2016-06-15 | 滨州医学院 | Astilbin merges the application in apoplexy medicine in preparation treatment or prevention diabetes |
| CN103768082A (en) * | 2012-10-18 | 2014-05-07 | 滨州医学院 | Application of astilbin to preparation of medicament for treating or preventing diabetes accompanied with stroke |
| CN103012522A (en) * | 2012-12-28 | 2013-04-03 | 顾玲 | Purification process of astilbin |
| CN103012522B (en) * | 2012-12-28 | 2015-03-25 | 顾玲 | Purification process of astilbin |
| CN111437302A (en) * | 2015-05-25 | 2020-07-24 | 蔡世珍 | Application of extract of engelhardtia leaves after water extraction and macroporous resin treatment in preparation of diabetes drugs and analysis method thereof |
| CN111437302B (en) * | 2015-05-25 | 2022-03-01 | 苏州优诺康医药科技有限公司 | Application of extract of engelhardtia leaves after water extraction and macroporous resin treatment in preparation of diabetes drugs and analysis method thereof |
| CN105061531A (en) * | 2015-07-29 | 2015-11-18 | 成都大学 | Astilbe chinensis glycoside derivatives and preparation method thereof |
| CN106565804A (en) * | 2016-10-10 | 2017-04-19 | 广西来宾绿翔生物科技有限公司 | Extraction technology of Engelhardia roxburghiana Wall leaf astilbin |
| CN107056858A (en) * | 2017-04-28 | 2017-08-18 | 南宁馨艺荣生物科技有限公司 | Process for extracting astilbin from engelhardtia leaves |
| CN107951923A (en) * | 2017-12-07 | 2018-04-24 | 广西壮族自治区中医药研究院 | A kind of preparation method of astragalus leaf flavonoids and its application in protection blood vessel drug eluting is prepared |
| CN109369749A (en) * | 2018-11-30 | 2019-02-22 | 陕西嘉禾生物科技股份有限公司 | A kind of preparation method of Astilbin |
| CN109369749B (en) * | 2018-11-30 | 2021-10-01 | 陕西嘉禾生物科技股份有限公司 | Preparation method of astilbin |
| CN111440221A (en) * | 2019-12-13 | 2020-07-24 | 湖南甜蔓生物科技有限公司 | Astilbin prepared from Engelhardtia chrysolepis Hance leaf and its preparation method |
| CN111440221B (en) * | 2019-12-13 | 2021-11-26 | 湖南甜蔓生物科技有限公司 | Astilbin prepared from Engelhardtia chrysolepis Hance leaf and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100348606C (en) | 2007-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100348606C (en) | Preparation method of astilbin | |
| CN102976909B (en) | Method for extracting and purifying 6-gingerol from ginger | |
| CN102351824B (en) | Method for preparing lactuca indica and lactucin | |
| CN106866602A (en) | A kind of method that application high speed adverse current chromatogram separates flavone compound in Hericium erinaceus | |
| CN102924416A (en) | Method for separating and purifying monomeric compounds from ash bark | |
| CN1289470C (en) | Process for rapid preparation of high pure pharmaceutical matters from patrinia villosa juss | |
| CN101337876A (en) | Process for extracting xanthohumol from lupulus | |
| CN106496292A (en) | A kind of method for preparing 6 iridoid glycoside constituents from Fructus Gardeniae simultaneously | |
| CN1307191C (en) | Process for preparing jasminodin and genipin-1-beta-D-gentiobioside with cape jasmine fruit | |
| CN101805347A (en) | Method for extracting bergapten from radix angelicae pubescentis | |
| CN103665065B (en) | A kind of method of preparing fast ponticin and rhapontigenin | |
| CN102070683A (en) | Method for simultaneously preparing chemical reference substances of parishin, parishin B and parishin C | |
| CN101565437B (en) | Separation and preparation method of patuletin-3-O-glucoside and astragalin | |
| CN103183658A (en) | Method for extracting effective component of coleus forskohlii | |
| CN102702289A (en) | Method for purifying three types of flavonoid glycosides from large-leaf poacynum leaves by applying high-speed counter-current chromatography | |
| CN102532147B (en) | Preparation method of high purity dictamnine monomer | |
| CN1431216A (en) | Method for extracting naringin | |
| CN101973861A (en) | Method for preparing germacrone | |
| CN103694293A (en) | Extraction purification method and detection method of tiliroside in loropetalum chinense | |
| CN101054404A (en) | Method of separating and preparing wild jujube seed saponin | |
| CN109369382B (en) | A method for preparing ginkgolic acids | |
| CN1919862A (en) | Method of extracting oleanolic acid from cockle pawpaw | |
| CN102093210A (en) | Purified preparation method of six ginkgoic acid monomers | |
| CN103242390A (en) | Method for extracting methyldeactylasperulosidate and Scandoside methyl ester | |
| CN101759640B (en) | Method for preparing high purity benzoylmesaconine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU ZHENGDA TIANQING PHARMACEUTICALS INDUSTRY |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100420 Address after: 210093 Life Science Institute, 22 Hankou Road, Jiangsu, Nanjing Co-patentee after: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Patentee after: Nanjing University Address before: 210093 Life Science Institute, 22 Hankou Road, Jiangsu, Nanjing Patentee before: Nanjing University |
|
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Patentee after: Nanjing University Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. Patentee before: Nanjing University |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071114 Termination date: 20180708 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |